Mallinckrodt to Merge with Stratatech Corporation
Mallinckrodt announced a planned merger agreement with Stratatech Corporation, a regenerative medicine company.
On August 10, 2016, Mallinckrodt announced that it has entered into a merger agreement with Stratatech Corporation, a privately held regenerative medicine company focused on the development of proprietary skin substitute products. Some developmental products include StrataGraft regenerative skin tissues and a platform for genetically enhanced skin tissues, Mallinckrodt said in a press announcement. The financial terms of the agreement were not disclosed, and Mallinckrodt anticipates the transaction will close in the second half of calendar 2016.
Stratatech Corporation is currently working on development of StrataGraft, which if approved, would be an off-the-shelf skin substitute product for the treatment of severe burns. StrataGraft is designed to produce living tissues that mimic human skin and promote tissue regeneration. The technology platform provides potential for new products through genetically enhanced tissues, applied topically, that produce elevated levels of natural wound healing and antimicrobial factors. Phase I development is underway in diabetic foot and venous leg ulcers, with other potential applications under consideration.
Source: Mallinckrodt
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
